As stimulation of TrkC by NT3 mimics the effects of β-adrenoceptors on UCP1 expression and adipocyte size in human and rodents, a drug selectively acting on TrkC, abundantly expressed in WAT and BAT, could be a promising pharmacological target in the management of obesity. Here, NTRK3 is linked to obesity disorder.